By Kelly Cloonan
Shares of Skye Bioscience rose after the company announced promising preclinical data for a drug combination including its new CB1 antibody nimacimab.
The stock was up 60% to $2.09 Tuesday. Shares have lost 84% over the past 12 months.
The biotechnology company said nimacimab combined with tirzepatide resulted in greater than 30% weight loss for mice in a diet-induced obesity model over 25 days.
Nimacimab alone demonstrated 24% weight loss, comparable with monlunabant and tirzepatide alone, the company said.
Chief Executive Punit Dhillon said data supports the company's belief that its antibody approach can provide meaningful efficacy without the risk of unwanted neuropsychiatric side effects that come with small molecule CB1 inhibitors like monlunabant.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 15, 2025 12:31 ET (16:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.